Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
1.220
-0.030 (-2.40%)
At close: May 8, 2025, 4:00 PM
1.180
-0.040 (-3.28%)
Pre-market: May 9, 2025, 8:00 AM EDT
Company Description
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.
The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer’s disease, and dementia.
It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues.
The company is based in Houston, Texas.
Nexalin Technology, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Sep 16, 2022 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Mark White |
Contact Details
Address: 776 Yorktown, Suite 550 Houston, Texas 77056 United States | |
| Phone | 832-260-0222 |
| Website | nexalin.com |
Stock Details
| Ticker Symbol | NXL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.15 |
| CIK Code | 0001527352 |
| CUSIP Number | 65345B201 |
| ISIN Number | US65345B2016 |
| Employer ID | 27-5566468 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Mark White | President, Chief Executive Officer, Chief Financial Officer and Director |
| Carolyn Shelton | Executive Vice President of Clinical, Quality and Regulatory Affairs and Chief Operating Officer |
| Dr. David Owens M.D. | Chief Medical Officer and Director |
| Marilyn Elson | Controller |
| John Patrick Claude | Co-Founder and Director of Engineering and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2025 | 8-K | Current Report |
| May 6, 2025 | 424B4 | Prospectus |
| May 5, 2025 | 424B5 | Filing |
| May 5, 2025 | 8-K | Current Report |
| May 2, 2025 | 424B4 | Prospectus |
| Apr 29, 2025 | EFFECT | Notice of Effectiveness |
| Apr 23, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 17, 2025 | 8-K | Current Report |
| Apr 15, 2025 | 10-K/A | [Amend] Annual report |
| Mar 31, 2025 | DRS | [Cover] Draft Registration Statement |